Saskatchewan to fund Elahere and Keytruda for eligible ovarian cancer patients from Dec. 1
Coverage begins December 1, 2026, for eligible patients whose ovarian cancer no longer responds to standard treatment. The province expects eight to 10 patients a year to benefit.
In this article & details
Saskatchewan will publicly fund Elahere and Keytruda for eligible patients with ovarian cancer beginning December 1, 2026, adding treatment options for people whose disease has stopped responding to standard care such as chemotherapy.
The provincial government announced the coverage expansion on November 17. It expects approximately eight to 10 patients in Saskatchewan each year to benefit from access to the two medicines.
Funding addresses a limited set of options after chemotherapy
The province described the additions as a response to a difficult point in ovarian cancer care: many patients initially respond to treatment, but options become more limited when standard chemotherapy no longer works. Ovarian cancer is frequently diagnosed at an advanced stage because its symptoms can be difficult to identify, the announcement noted.
The funding commitment applies to patients who meet the eligibility requirements for the relevant treatment. The announcement names two medicines; it does not describe them as a two-drug regimen to be administered together.
According to the government, clinical studies showed benefits in survival and delaying progression of the disease. The release does not provide the trial results or detailed patient-selection criteria for either medicine. Its stated next step for patients who may qualify is a discussion with their treating oncologist about the available options.
National reviews and pricing negotiations preceded coverage
Saskatchewan says its decision follows national assessments of safety, effectiveness and value, along with pricing negotiations through the pan-Canadian Pharmaceutical Alliance. The December 1 start date is the provincial coverage decision that follows those steps.
Health Minister Jeremy Cockrill said the additions are intended to expand access to innovative treatment close to home. Saskatchewan Cancer Agency vice-president of care services Denise Budz said the agency’s work with national partners supports access to evidence-based therapies and specialized care.
Ovarian Cancer Canada welcomed the announcement. Chief executive Tania Vrionis said the decision followed months of advocacy by thousands of Canadians and would reduce financial barriers for patients and families awaiting additional treatment choices. The charity said it wanted to see similar progress continue elsewhere in Canada.
The province placed the decision within its wider cancer-care investment. The Saskatchewan Cancer Agency’s 2026–27 budget is $308.6 million, covering prevention, early detection, diagnosis, treatment, research and patient support. The release did not identify a separate dollar amount for the Elahere and Keytruda coverage expansion.
Coverage takes effect on December 1 for eligible patients, with treatment selection handled through their oncology care.
References
- Saskatchewan Expands Access to New Ovarian Cancer Treatments — Government of Saskatchewan, November 17, 2026; coverage from December 1
Discussion
0 commentsJoin the discussion. Anyone can read the comments. To comment, log in or create a free individual account.
No comments yet.